These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

455 related articles for article (PubMed ID: 12379628)

  • 21. High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor alpha inhibitors in rheumatoid arthritis.
    Bobbio-Pallavicini F; Caporali R; Alpini C; Avalle S; Epis OM; Klersy C; Montecucco C
    Ann Rheum Dis; 2007 Mar; 66(3):302-7. PubMed ID: 17079248
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dermatomyositis in patients with rheumatoid arthritis during adalimumab therapy.
    Nagashima T; Minota S
    J Rheumatol; 2011 Mar; 38(3):574; author reply 575. PubMed ID: 21362792
    [No Abstract]   [Full Text] [Related]  

  • 23. Adalimumab.
    Bain B; Brazil M
    Nat Rev Drug Discov; 2003 Sep; 2(9):693-94. PubMed ID: 12953696
    [No Abstract]   [Full Text] [Related]  

  • 24. [Autoimmune aspects of treatment with TNF-alpha inhibitors].
    Kolarz B; Targońska-Stepniak B; Darmochwał-Kolarz D; Majdan M
    Postepy Hig Med Dosw (Online); 2007 Aug; 61():478-84. PubMed ID: 17786135
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Summary of clinical trials in rheumatoid arthritis using infliximab, an anti-TNFalpha treatment.
    Harriman G; Harper LK; Schaible TF
    Ann Rheum Dis; 1999 Nov; 58 Suppl 1(Suppl 1):I61-4. PubMed ID: 10577975
    [No Abstract]   [Full Text] [Related]  

  • 26. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.
    Smolen JS; Kay J; Doyle MK; Landewé R; Matteson EL; Wollenhaupt J; Gaylis N; Murphy FT; Neal JS; Zhou Y; Visvanathan S; Hsia EC; Rahman MU;
    Lancet; 2009 Jul; 374(9685):210-21. PubMed ID: 19560810
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Biologicals in the treatment of rheumatic diseases].
    Scherer HU; Burmester GR
    Dtsch Med Wochenschr; 2006 Oct; 131(41):2279-85. PubMed ID: 17036270
    [No Abstract]   [Full Text] [Related]  

  • 28. Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial.
    Burmester GR; Mariette X; Montecucco C; Monteagudo-Sáez I; Malaise M; Tzioufas AG; Bijlsma JW; Unnebrink K; Kary S; Kupper H
    Ann Rheum Dis; 2007 Jun; 66(6):732-9. PubMed ID: 17329305
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adalimumab - a new TNF-alpha antibody for treatment of inflammatory joint disease.
    Machold KP; Smolen JS
    Expert Opin Biol Ther; 2003 Apr; 3(2):351-60. PubMed ID: 12662147
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bone erosion repair with adalimumab in rheumatoid arthritis.
    Ros-Expósito S; Ruiz-Martín JM; Sanz-Frutos P; De La Fuente De Dios D
    Clin Rheumatol; 2010 Nov; 29(11):1339-40. PubMed ID: 20697763
    [No Abstract]   [Full Text] [Related]  

  • 31. Onset of systemic lupus erythematosus after conversion of infliximab to adalimumab treatment in rheumatoid arthritis with a pre-existing anti-dsDNA antibody level.
    van Rijthoven AW; Bijlsma JW; Canninga-van Dijk M; Derksen RH; van Roon JA
    Rheumatology (Oxford); 2006 Oct; 45(10):1317-9. PubMed ID: 16844698
    [No Abstract]   [Full Text] [Related]  

  • 32. Adalimumab in juvenile rheumatoid arthritis.
    de Vries MK; van der Horst-Bruinsma IE; Wolbink GJ
    N Engl J Med; 2008 Dec; 359(23):2496; author reply 2496-7. PubMed ID: 19065700
    [No Abstract]   [Full Text] [Related]  

  • 33. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.
    Strangfeld A; Listing J; Herzer P; Liebhaber A; Rockwitz K; Richter C; Zink A
    JAMA; 2009 Feb; 301(7):737-44. PubMed ID: 19224750
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Undermanagement of patients with rheumatism. Know-how too often not utilized].
    Bischoff A
    MMW Fortschr Med; 2003 Nov; 145(47):4-5. PubMed ID: 14725023
    [No Abstract]   [Full Text] [Related]  

  • 35. Response to: 'Drug survival on TNF inhibitors: 2003-2004 data from Italian National Register (GISEA Register)' by Iannone et al.
    Neovius M; Askling J
    Ann Rheum Dis; 2014 Jun; 73(6):e32. PubMed ID: 24638970
    [No Abstract]   [Full Text] [Related]  

  • 36. [Tumour necrosis factor alpha antagonists in established rheumatoid arthritis: effectiveness comparative study].
    Arenere Mendoza M; Manero Ruiz FJ; Carrera Lasfuentes P; Navarro Aznárez H; Pecondón Español A; Rabanaque Hernández MJ
    Med Clin (Barc); 2010 May; 134(15):665-70. PubMed ID: 20363004
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Anti-TNF alpha in the treatment of rheumatoid arthritis and ankylosing spondylitis].
    Lanfant-Weybel K; Lequerré T; Vittecoq O
    Presse Med; 2009 May; 38(5):774-87. PubMed ID: 19327945
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treating rheumatoid arthritis with tumour necrosis factor alpha blockade.
    Emery P; Buch M
    BMJ; 2002 Feb; 324(7333):312-3. PubMed ID: 11834544
    [No Abstract]   [Full Text] [Related]  

  • 39. Effect of adalimumab on neutrophil function in patients with rheumatoid arthritis.
    Capsoni F; Sarzi-Puttini P; Atzeni F; Minonzio F; Bonara P; Doria A; Carrabba M
    Arthritis Res Ther; 2005; 7(2):R250-5. PubMed ID: 15743471
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-tumor necrosis factor-alpha agents for rheumatoid arthritis: assessing longterm safety.
    Hyrich KL; Silman AJ
    J Rheumatol; 2006 May; 33(5):831-3. PubMed ID: 16652412
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.